OCUL vs. PCVX, KRYS, CYTK, RYTM, PTCT, SRPT, RNA, SWTX, RARE, and AKRO
Should you be buying Ocular Therapeutix stock or one of its competitors? The main competitors of Ocular Therapeutix include Vaxcyte (PCVX), Krystal Biotech (KRYS), Cytokinetics (CYTK), Rhythm Pharmaceuticals (RYTM), PTC Therapeutics (PTCT), Sarepta Therapeutics (SRPT), Avidity Biosciences (RNA), SpringWorks Therapeutics (SWTX), Ultragenyx Pharmaceutical (RARE), and Akero Therapeutics (AKRO). These companies are all part of the "pharmaceutical products" industry.
Ocular Therapeutix vs.
Vaxcyte (NASDAQ:PCVX) and Ocular Therapeutix (NASDAQ:OCUL) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, community ranking, institutional ownership and media sentiment.
Vaxcyte presently has a consensus target price of $136.50, suggesting a potential upside of 302.06%. Ocular Therapeutix has a consensus target price of $16.25, suggesting a potential upside of 125.07%. Given Vaxcyte's stronger consensus rating and higher probable upside, equities research analysts clearly believe Vaxcyte is more favorable than Ocular Therapeutix.
Ocular Therapeutix received 388 more outperform votes than Vaxcyte when rated by MarketBeat users. However, 78.57% of users gave Vaxcyte an outperform vote while only 70.32% of users gave Ocular Therapeutix an outperform vote.
96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are held by institutional investors. 3.1% of Vaxcyte shares are held by company insiders. Comparatively, 2.3% of Ocular Therapeutix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Ocular Therapeutix has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.
Vaxcyte has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, Ocular Therapeutix has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500.
In the previous week, Vaxcyte had 5 more articles in the media than Ocular Therapeutix. MarketBeat recorded 15 mentions for Vaxcyte and 10 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 1.56 beat Vaxcyte's score of 1.41 indicating that Ocular Therapeutix is being referred to more favorably in the news media.
Vaxcyte has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -283.74%. Vaxcyte's return on equity of -23.53% beat Ocular Therapeutix's return on equity.
Summary
Vaxcyte beats Ocular Therapeutix on 11 of the 18 factors compared between the two stocks.
Get Ocular Therapeutix News Delivered to You Automatically
Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ocular Therapeutix Competitors List
Related Companies and Tools
This page (NASDAQ:OCUL) was last updated on 5/23/2025 by MarketBeat.com Staff
Buy OCUL Stock Free OCUL Stock Alerts